Drug intelligence / Profile preview

Gemolac

Development stage: Unknown
Lead developer: Allgems Healthcare
Modality: Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
Administration: Oral

Overview

Gemolac is an oral probiotic supplement developed by Allgems Healthcare, categorized within their gastrointestinal (GI) branded generics portfolio. It is indicated for the maintenance of gastrointestinal health and the treatment of dysbiosis, a condition involving an imbalance of the gut's microbial community. As a probiotic, Gemolac introduces beneficial live microorganisms into the digestive tract to restore the natural flora, which may be disrupted by factors such as antibiotic therapy, infections, or poor diet. Its mechanism of action involves the competitive exclusion of pathogenic bacteria, the production of antimicrobial substances (such as organic acids), and the enhancement of the intestinal mucosal barrier and local immune response. It is typically used to manage digestive upsets, including diarrhea and irritable bowel syndrome (IBS).

Brand names: Gemolac

Beyond the preview

Go deeper on Gemolac.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Gemolac.

Explore the full profile